Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37343514.
- Also identified by DOI 10.1016/j.xcrm.2023.101071 and PMC identifier 10313925.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.<sup>1</sup>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Neuroblastoma